Potassium sodium-activated channel subfamily T member 1 (KCNT1) (KCNT1)

Potassium sodium-activated channel subfamily T member 1 (KCNT1), also known as Slack, is a sodium-activated potassium channel that plays a critical role in regulating neuronal excitability by contributing to the slow afterhyperpolarization following action potentials [UniProt: Q5JUK3]. It is widely expressed in the central nervous system, where it modulates the rate of repetitive firing in neurons [NCBI Gene: 375795]. Gain-of-function mutations in the KCNT1 gene, such as the F313L variant, lead to increased channel conductance and are the primary cause of severe early-onset epilepsies, including epilepsy of infancy with migrating focal seizures (EIMFS) and autosomal dominant sleep-related hypermotor epilepsy (ADSHE) [PubMed: 22541558]. These conditions are often refractory to conventional anti-seizure medications, making KCNT1 a high-priority therapeutic target [PubMed: 30355514]. Current drug development efforts focus on identifying selective small-molecule inhibitors and antisense oligonucleotides (ASOs) to reduce the overactive potassium current or decrease KCNT1 protein levels [Praxis Precision Medicines]. While the anti-arrhythmic drug quinidine has been used off-label to treat KCNT1-related epilepsy, its clinical utility is limited by poor brain penetration and significant cardiac safety concerns, such as QT prolongation [PubMed: 24514153]. Consequently, there is an urgent need for more potent and CNS-selective KCNT1 modulators to improve patient outcomes.

Other names

SlackKCa4.1Slo2.2Sodium-activated potassium channel protein 1KCNT1BAMTFEEIMFSENFL5

The primary mechanism of action for drugs targeting KCNT1 involves the inhibition of the channel's potassium conductance to counteract gain-of-function mutations [PubMed: 24514153]. This can be achieved through direct pore blockade or negative allosteric modulation by small molecules. Additionally, antisense oligonucleotides (ASOs) are being developed to selectively bind to KCNT1 mRNA, leading to its degradation and a subsequent reduction in the expression of the overactive protein [Praxis Precision Medicines].